Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | TGM2 | P21980 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22576799 | 1.00 | HTT (0.63) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL234108 | 0.88 | HTT (0.64) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL10251482 | 0.88 | EPHX2 (0.54) | HTTTGM2LMNAMEN1KMT2A | |
| SCHEMBL9340146 | 0.85 | HTT (0.79) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL9874334 | 0.85 | HTT (0.79) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL15346534 | 0.85 | HTT (0.79) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL10254895 | 0.85 | EPHX2 (0.49) | HTTLMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL18254066 | 0.83 | HTT (0.81) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL18751657 | 0.83 | HTT (0.76) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL7159271 | 0.82 | HTT (0.62) | HTTTGM2LMNASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12427187-B2 | Glucose-responsive insulin conjugates | MERCK SHARP & DOHME LLC (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4615487-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20240424109-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4436610-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2024102633-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| US-11820805-B2 | Conjugate based systems for controlled insulin delivery | MERCK SHARP & DOHME LLC (US) | 2023-11-21 | — | — | US | disclosed |
| WO-2023091441-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2023-05-25 | — | — | WO | disclosed |
| US-11413352-B2 | Conjugate based systems for controlled insulin delivery | Merck, Sharp & Dohme LLC (US) | 2022-08-16 | — | — | US | disclosed |
| US-20220233647-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2022-07-28 | — | — | US | disclosed |
| US-20210198339-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2021-07-01 | — | — | US | disclosed |
| US-11041009-B2 | Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes | MERCK SHARP & DOHME CORP. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20210177981-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | MERCK SHARP & DOHME CORP. (US) | 2021-06-17 | — | — | US | disclosed |
| WO-2020247297-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-3740212-A2 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | Merck Sharp & Dohme Corp. (US) | 2020-11-25 | — | — | EP | disclosed |
| EP-3727424-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | Merck Sharp&Dohme Corp. (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200087375-A1 | GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2020-03-19 | — | — | US | disclosed |
| EP-3600381-A1 | GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme Corp. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2018175272-A1 | GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME CORP. (US) | 2018-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210177981-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | GPR119, INSR, IGF1R | HTT 2039/4885TGM2 1094/4885LMNA 2735/4885 |
| US-12427187-B2 | Glucose-responsive insulin conjugates | GPR119, IRS1, INSR | HTT 817/4885TGM2 1352/4885LMNA 4836/4885 |
| US-20220233647-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES | GPR119, IRS1, INSR | HTT 817/4885TGM2 1352/4885LMNA 4836/4885 |
| US-11820805-B2 | Conjugate based systems for controlled insulin delivery | GPR119, INSR, IGF1R | HTT 1774/4885TGM2 1076/4885LMNA 2410/4885 |
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | INSR, GPR119, GLP1R | HTT 1719/4885TGM2 1041/4885LMNA 4564/4885 |
| US-11413352-B2 | Conjugate based systems for controlled insulin delivery | GPR119, INSR, IGF1R | HTT 2039/4885TGM2 1094/4885LMNA 2735/4885 |
| US-20210198339-A1 | CONJUGATE BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY | GPR119, INSR, IGF1R | HTT 1774/4885TGM2 1076/4885LMNA 2410/4885 |
| US-20200087375-A1 | GLUCOSE RESPONSIVE INSULIN COMPRISING A TRI-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | GPR119, IAPP, INSR | HTT 2533/4885TGM2 1452/4885LMNA 4430/4885 |
| US-11041009-B2 | Glucose responsive insulin comprising a tri-valent sugar cluster for treatment of diabetes | GPR119, IAPP, INSR | HTT 2533/4885TGM2 1452/4885LMNA 4430/4885 |
| US-20240424109-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | GPR119, INSR, IAPP | HTT 982/4885TGM2 659/4885LMNA 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.